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Abstract
In the search for an effective vaccine against the human immunodeficiency virus (HIV), novel ways to deliver viral antigens are being
evaluated. One such approach is the use of nonreplicating viral vectors encoding HIV and/or SIV genes that are expressed after infection
of host cells. Nonreplicating poliovirus vectors, termed replicons, that expressed HIV-1/HXB2 and SIVmac239 gag and various HIV-1 env
genes from different clades were tested for immunogenicity and protective efficacy against intravenous challenge of pig-tailed macaques
with SHIV-89.6P. To maximize both cellular and humoral immune responses, a prime-boost regimen was used. Initially, macaques were
immunized four times over 35 weeks by either the intranasal and intrarectal or the intramuscular (im) route with mixtures of poliovirus
replicons expressing HIV-1 gag and multiple env genes. Immunization with replicons alone induced both serum antibodies and lymphocyte
proliferative responses. After boosting with purified Env protein, neutralizing antibodies to SHIV-89.6P were induced in four of five
immunized animals. In a second experiment, four macaques were immunized im three times over 27 weeks with replicons expressing the
SIVmac239 gag and HIV-1/HXB2 env genes. All immunized animals were then boosted twice with purified HIV-1-89.6 rgp140-Env and
SIVmac239 p55-Gag proteins. Four control animals received only the two protein inoculations. Immunized and control animals were then
challenged intravenously with the pathogenic SHIV-89.6P. After challenge the animals were monitored for virus isolation from peripheral
blood mononuclear cells and plasma viremia and for changes in virus-specific antibody titers. Naı¨ve pig-tailed macaques experienced rapid
loss of CD4 T cells and died between 38 and 62 weeks after infection. In contrast, macaques immunized with replicons and proteins rapidly
cleared plasma virus and did not experience sustained loss of CD4 lymphocytes. Furthermore, two of the four macaques that were
immunized only with purified proteins maintained high viral burdens and lost greater than 95% of their CD4 lymphocytes within 2 to 4
weeks after challenge. Thus, poliovirus replicons expressing HIV-1 and SIV antigens were immunogenic in pig-tailed macaques and
appeared to enhance the protective effects observed after administration of purified proteins alone.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
The current view within the scientific community in-
volved in preclinical and clinical testing of potential human
immunodeficiency virus type 1 (HIV-1) vaccines for effi-
cacy is that protection against disease progression, rather
than infection, is the more realistic goal (Kumar and
Narayan, 2001; Letvin, 2002). This idea is supported by
numerous studies in which macaques were immunized with
HIV-1 and/or simian immunodeficiency virus (SIV) anti-
gens and then challenged with one of several infectious SIV
strains or chimeric simian/human immunodeficiency viruses
(SHIV) (Israel et al., 1994; Belyakov et al., 2001; Shiver et
al., 2002). For a vaccine to provide maximum protection
against SIV/SHIV and HIV-1 transmission, humoral and
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cellular, as well as parenteral and mucosal immune re-
sponses, should be elicited (Nathanson and Mathieson,
2000). All of these are necessary since HIV-1 is transmitted
as either cell-free or cell-associated virus and most new
HIV-1 infections are acquired through either sexual activity
or, to a lesser extent, intravenously among injecting drug
users. Furthermore, a vaccine should elicit broad cross-
reactive immunity because of the extreme genetic variation
among the hundreds of HIV-1 isolates sequenced to date
(Walker and Korber, 2001; Gaschen et al., 2002).
Multiple approaches for making candidate HIV vaccines
have been employed; these include purified recombinant
proteins and peptides and replicating or nonreplicating vec-
tors that express SIV and HIV antigens. The live replicating
vectors tested to date in the macaque model include atten-
uated SIV or SHIV strains (Marthas et al., 1990; Daniel et
al., 1992; Wyand et al., 1996; Shibata et al., 1997; Johnson
et al., 1999; Kumar et al., 2001), recombinant poxviruses
(Andersson et al., 1996; Ourmanov et al., 2000), herpes
simplex virus (Murphy et al., 2000), adenovirus (Buge et al.,
1997), poliovirus (Crotty et al., 1999, 2001), rabies virus
(Schnell et al., 2000), vesicular stomatitis virus (Rose et al.,
2001), and Semliki Forest virus (Mossman et al., 1996;
Berglund et al., 1997). Nonreplicating vaccine vectors in-
clude canarypox (Andersson et al., 1996), Venezuelan
equine encephalitis (VEE) virus replicons (Davis et al., 2000),
phage-display (Chen et al., 2001), and naked DNA (Lu et
al., 1996; Barouch et al., 2000; Egan et al., 2000; Gorelick
et al., 2000; Amara et al., 2001; Cherpelis et al., 2001). All
of the above approaches have had variable levels of success
at inducing both humoral and/or cellular responses and
providing protection against both parenteral and mucosal
infection or disease after SIV or SHIV challenge.
That both humoral and cellular immune responses can
effectively contribute to protection against SIV or SHIV
infection or disease has been demonstrated in the macaque
model. Passive immunization with either neutralizing
monoclonal or serum antibodies has resulted in various
levels of protection from disease progression after intrave-
nous inoculation of virus or exposure of virus to mucosal
surfaces (Joag et al., 1999; Mascola et al., 1999, 2000;
Shibata et al., 1999; Baba et al., 2000; Parren et al., 2001).
The importance of CD8 cytotoxic T-lymphocyte (CTL)
activity was demonstrated by depleting CD8 cells during
acute or chronic infections with SIV or SHIV, which re-
sulted in increased levels of virus (Matano et al., 1998;
Schmitz et al., 1999; Metzner et al., 2000). To optimize both
humoral and cellular immune responses, the more recent
vaccination regimens have consisted of priming with one
type of immunogen and boosting with a second type, e.g.,
recombinant vaccinia virus or DNA followed by purified
protein (Hu et al., 1992; Letvin et al., 1997; Putkonen et al.,
1998; Polacino et al., 1999; Gorelick et al., 2000) or a
combination of a recombinant vaccinia or fowl pox virus
and DNA (Robinson et al., 1999; Hel et al., 2001). The
immunogens based on replicating vectors or DNA primarily
elicit CTL, whereas protein antigens are more effective at
inducing antibodies (Letvin, 2002).
Because HIV is transmitted primarily across mucosal
surfaces, HIV vaccines must induce long-lasting protective
responses in these tissues. Protection against pathogenic
SIV and SHIV infections by vaginal and rectal challenge of
immunized macaques has been achieved with some of the
immunogens described above. One way in which mucosal
immunity has been optimized is by delivering immunogens
directly to mucosal surfaces or to the gastrointestinal tract
where gut-associated lymphoid tissue is located (Staats et
al., 1997; Imaoka et al., 1998; Crotty et al., 1999; Wang et
al., 2000). Poliovirus is stable in the intestinal environment
and attenuated strains have been used effectively to eradi-
cate poliomyelitis from most countries in the world. Using
two cocktails of 20 recombinant poliovirus vectors express-
ing multiple SIV gene fragments, Crotty et al. (2001) dem-
onstrated protection against disease development and, in
two of seven animals, possible protection against infection
after vaginal challenge with SIVmac251. As an alternative
approach, we generated poliovirus vectors, termed repli-
cons, to deliver viral genes that could be translated into
antigens (Ansardi et al., 1993; Porter et al., 1993). Replicons
consist of the poliovirus genome in which the P1 capsid
protein has been replaced by a gene of interest. Transfection
of a replicon genome into a cell expressing the capsid
protein supplied in trans leads to production of fully encap-
sidated particles that can infect target cells and replicate.
However, because the replicons encode no P1 protein, only
one round of infection and replication can occur, eliminat-
ing any possible pathogenic effects from this vaccine vector.
To evaluate their possible use as a component of an
HIV-1 vaccine, poliovirus replicons expressing various
HIV-1 and SIV genes were constructed and used initially to
evaluate immunogenicity and subsequently to assess effi-
cacy using a prime-boost regimen. We report here that
immunization with poliovirus replicons followed by puri-
fied recombinant proteins provided protection, primarily
from disease sequelae, comparable to that obtained by oth-
ers in prime-boost protocols using different types of immu-
nogens.
Results
Experiment 1. Immunogenicity of poliovirus replicons
In an initial experiment to determine whether poliovirus
replicons expressing various HIV-1 Env and SIVmac239
Gag antigens would be immunogenic in macaques, five
animals were immunized with a mixture of replicons (de-
scribed under Materials and methods and in Table 1) by a
combination of nasal and rectal administration, according to
the protocol shown in Fig. 1 and explained in more detail
under Materials and methods. Antibodies to HIV-1 were not
detected until after the fourth inoculation of replicons at
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week 35, demonstrating that this method of antigen delivery
can induce a humoral immune response after multiple ad-
ministrations (Fig. 2). Antibody titers declined over time,
but persisted until week 66 and then increased when the five
animals were boosted with 100 g of purified HIV-1-89.6
rgp140-Env emulsified with incomplete Freund’s adju-
vant. Similarly, when a second inoculation of HIV-1-89.6
rgp140-Env was done at week 85, antibody titers again
increased after having declined. At 2 weeks after the second
inoculation of purified protein (week 87), four of the five
macaques had serum antibodies that neutralized SHIV-89.6,
but not SHIV-IIIB. These neutralization titers, which were
detected in serum from all but macaque M463, ranged from
1:61 to 1:355 in a MT2 cell-killing assay (Montefiore et al.,
1996), but within 2 weeks the titers declined by approxi-
mately 50% (data not shown).
To evaluate induction of cell-mediated HIV-1-specific
immune responses, peripheral blood mononuclear cells
(PBMC) from the immunized animals were tested for the
ability to proliferate in response to purified HIV-1 antigens.
Four weeks after the second inoculation of protein, all five
immunized macaques had PBMC that proliferated in re-
sponse to purified HIV-1-89.6 rgp120-Env and four of the
five animals had responses to HIV-1-SF2 p24 Gag (Fig. 3).
That the levels of proliferation to Gag were lower than those
to Env is not surprising since the macaques were exposed to
Gag antigens only by immunization with replicons and
never received an inoculation of Gag protein. Therefore, the
results indicate that poliovirus replicons are immunogenic
in macaques and that a prime-boost regimen with replicons
and protein elicited both neutralizing antibodies and CD4
T cell helper activity.
Although the animals were challenged intravenously (iv)
with a low dose of SHIV-89.6P, the results of this challenge
and a second one of these same animals with a higher dose
of virus were not easily interpreted since the control animals
did not appear to be infected after the first challenge. Be-
cause of the two virus challenges and the ambiguous nature
of the experiment, only the viral loads and loss of CD4
lymphocytes in the three control animals are presented here
to demonstrate that SHIV-89.6P induces the same effects on
CD4 T cells in pig-tailed as in rhesus macaques (Fig. 4A).
Similar observations on the effects of different SHIVs on
CD4 T cells in pig-tailed macaques have been reported by
others (Joag et al., 1997; McCormick-Davis et al., 1998;
Table 1
Proteins expressed by poliovirus replicons that were used as
immunogens
Strain Gene Clade Comments
Experiment 1
92RW020 env (TM) A gp120
92BR025 env (TM) C gp120
92TH022 env (TM) E gp120
92UG021 env (TM) D gp120
IIIB/LAI (HXB2) env (TM) B gp120
env B gp140; lacks signal sequence
env B gp120  gp41ectodomain
gag B p55 Gag fused to VP4
92RW009 env A gp160
92TH026 env B gp160
Experiment 2
IIIB/LAI (HXB2) env (TM) B gp120
SIVmac239 gag NA p55
Note. With the exception of strain IIIB/LAI, the HIV-1 isolates from
which gp160 molecular clones were made and used to generate replicons
were described by Gao et al. (1994, 1996). NA, not applicable.
Fig. 1. Immunization schedules for poliovirus replicons and purified proteins. Experiment 1: Macaques were immunized at the times indicated with replicons
expressing env genes from the HIV-1 strains shown and HIV-1-HXB2 gag. At weeks 66 and 85, HIV-1-89.6 rgp140-Env in incomplete Freund’s adjuvant
was administered intramuscularly. Experiment 2: Poliovirus replicons expressing HIV-1-LAI/IIIB env and SIVmac239 gag genes were administered im at
weeks 0, 4, and 27, followed by HIV-1-89.6 rgp140-Env and SIVmac239 p55 Gag at weeks 41 and 60. Intravenous challenge with SHIV-89.6P was done
at week 63. Purified proteins are indicated by antigens being italicized and underlined.
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Pullium et al., 2001). Virus was isolated from PBMC from
the three naı¨ve controls at 1 week after the second challenge
and multiple times thereafter. Likewise, evaluation of
plasma virion RNA levels by NASBA, which had a cutoff
value of 104 copies, revealed high levels of viremia in
plasma from the three control animals with a set-point
greater than 105 RNA copies per milliliter of plasma (Fig.
4B). Macaque 95P003 was the only control animal to de-
velop measurable antibodies to HIV-1 or SIV. Failure of the
other two control animals to produce detectable serum an-
tibodies was most likely a result of rapid loss of CD4 T
cells by 4 weeks after challenge (Fig. 4A). The three control
animals became moribund and were euthanized at 38, 44,
and 62 weeks.
Experiment 2. Immunizations
The first experiment utilized multiple replicons express-
ing different HIV-1 env genes and demonstrated that polio-
Fig. 2. Induction of antibodies to HIV-1 by poliovirus replicons expressing multiple HIV-1 env genes (Experiment 1). The open “down” arrows indicate
intranasal and intrarectal immunization and the solid down arrows, intramuscular administration of replicons. Macaques M463, M552, and M907 also
received the Sabin poliovirus types 1 and 2 vaccine strains. The “up” arrows indicate times of intramuscular inoculation of recombinant proteins. EIA
antibody titers are defined as the last dilution of serum to give an OD reading above the cutoff value.
Fig. 3. Proliferation of PBMC in response to mitogen or purified recom-
binant HIV-1 proteins. Antigens were HIV-1-89.6 gp120-Env and HIV-1-
SF2 p24 Gag; macaque 95P003 was an unimmunized control. Values
above the dashed line are considered positive.
Fig. 4. Percentages of CD4 lymphocytes (A) in peripheral blood and
virion RNA levels (B) in plasma after infection of unimmunized pig-tailed
macaques with SHIV-89.6P. Times of death are indicated by the crosses.
The level of sensitivity of NASBA was 104 copies per ml.
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virus replicons were immunogenic. However, because most
of the animals had to be inoculated with the challenge virus
twice, a second, more straightforward experiment was de-
signed to assess the role of priming with replicons and
boosting with protein compared to immunizing only with
purified HIV-1 proteins. Two groups of four macaques each
were used. The experimental group was immunized three
times over a period of 27 weeks with equal amounts of a
replicon expressing the HIV-I-LAI/IIIB env gene and one
expressing SIVmac239 gag (Fig. 1). All eight animals were
then immunized twice with a mixture of purified rgp140-
Env from the HIV-1-89.6 strain and purified SIVmac239
Gag. Using commercial whole virus ELISA kits, none of the
animals had detectable antibodies to SIV or HIV-1 follow-
ing immunization with replicons. A low level of antibodies
(titer, 1:50) that recognized SIVmac239 Gag was detected
in only one of the animals after the first booster inoculation
of purified proteins. However, 3 weeks after the second
protein injection, all eight animals rapidly developed serum
antibodies to SIVmac239 Gag, with titers that ranged from
1:50 to 1:10,000 (Fig. 5A, week 0). Likewise, antibodies
(range 1:50 to 1:400) to HIV-1 Env immunogens were not
detected in serum samples from any of the animals until
after the second protein boost (Fig. 5B). The overall lower
antibody titers to HIV-1 probably reflected the fact that the
ELISA kits were made with whole virus lysates that usually
contain more Gag than Env protein. At the time of chal-
lenge, none of the animals had detectable serum neutralizing
antibodies to SHIV-HXB2 or SHIV-89.6.
The ability of PBMC from the animals to proliferate in
response to HIV-1 and SIV antigens also was tested peri-
odically. Within 2 weeks after the second replicon immu-
nization (week 6), three of the four macaques had PBMC
that proliferated in response to SIVmac239 Gag (Fig. 6), but
there was no reactivity to HIV-I-LAI/IIIB rgp120-Env (not
shown). These Gag-specific responses persisted in PBMC
from all four macaques until week 27, when the third inoc-
ulation of replicons was administered. In general, responses
waned after the protein boosts (done at weeks 41 and 60)
and were not present at time of challenge (week 63). These
Fig. 5. Antibody titers to SIVmac239 Gag (A) and HIV-1 Env (B) at time of and after iv challenge (solid vertical line) of immunized macaques with
SHIV-89.6P. Macaques were immunized with poliovirus replicons and recombinant proteins (solid symbols) or only recombinant proteins (open symbols).
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results clearly show that, after intramuscular inoculation,
poliovirus replicons can elicit a cellular response to ex-
pressed antigens.
Although no proliferative responses to rgp120-Env de-
rived from the HIV-1-IIIB strain were detected at any time,
when the HIV-1-89.6 rgp120-Env was used to stimulate
cells at week 41, surprisingly, responses (stimulation indi-
ces of 9.08 and 9.12, respectively) were present in two
(97P009 and 95P016) of the animals that were primed with
the replicons. One reason that might explain the lack of
proliferation to HIV-1-IIIB Env is that the quality of the
HIV-1-IIIB rgp120-Env protein was not comparable to that
of the HIV-1-89.6 rgp120-Env. Irrespective of the reason
for these disparate results, they indicate that cross-reactive
responses were present. These proliferative responses to
Gag and Env, that were detected at 41 weeks, decreased
immediately after the protein boost, but had increased by
week 60 when the second immunization with purified pro-
teins occurred. Such apparent down-regulation of immune
responses after multiple vaccinations is not unusual and has
been observed in the SIV-macaque and HIV-chimpanzee
models (Lubeck et al., 1994; Putkonen et al., 1998; Kumar
et al., 2000; Murphy et al., 2000).
Challenge of macaques
At 3 weeks after the second protein boost, all eight
macaques were challenged iv with 10 to 100 animal infec-
tious doses (AID) of SHIV-89.6P. Following challenge,
virus was isolated on multiple occasions from PBMC from
all but one animal (95P016). Consistent with these results,
viremia peaked at 2 weeks after inoculation in seven ani-
mals, but plasma RNA was detected only once, at 6 weeks
(250 copies/ml of plasma), in 95P016, the animal from
which virus was never isolated from PBMC (Figs. 7A and
7C). In addition, all animals except 95P016 maintained
relatively high titers of antibodies after challenge (Fig. 5).
At 1 week after challenge, proliferative responses to SIV-
mac239 Gag were elevated in the four replicon-immunized
animals, but only one control macaque (97P004) that was
inoculated with proteins had such a response [stimulation
index (SI)  3.28]. All animals experienced at least a
transient drop in CD4 cell numbers (Figs. 7B and D), but
only two of the control animals, immunized only with Env
protein, had persistently low levels of CD4 cells (Fig. 7D).
One of these animals, 97P002, had persistent diarrhea and
was euthanized at 28 weeks with essentially no CD4 T
cells in its peripheral circulation and lymph nodes. Proximal
cause of death was severe rectal prolapse with a necrotic
colon. The other seven macaques were euthanized at 87
weeks when the study was terminated. At that time, one
control animal (97P005) that had been immunized only with
protein was anemic and had chronic diarrhea and 100
CD4 lymphocytes. Although the number of animals in the
two groups was small, the results of this experiment sug-
gested that priming with poliovirus replicons expressing
HIV-1 Env and SIV Gag antigens enhanced the ability of
purified recombinant Env and Gag proteins to prevent loss
of CD4 T cells, delay disease progression, and in two
cases (96P008 and 95P016), reduce viremia to undetectable
levels early after SHIV-89.6P infection.
Measurement of cytokines
Because the ability of macaques to clear SIVmac239
rapidly from blood is associated with detectable levels of
interferon (IFN)- in serum at the time of virus inoculation
(Fultz et al., unpublished data), we tested serum samples
obtained immediately before challenge to determine the
concentrations of IFN- and interleukin (IL)-12, another
cytokine associated with T-helper type 1 (Th1) immune
responses. There was no correlation between serum concen-
trations of these two cytokines and different levels of pro-
tection (Table 2). Animals with the highest levels of IFN-
(96P001, 908 pg/ml; 97P004, 526 pg/ml) also had high
plasma RNA copy numbers, whereas animals with no de-
Fig. 6. Proliferative responses to SIVmac239 Gag of macaques immunized with both poliovirus replicons and recombinant proteins. Values above the line
(SI  2.0) are considered positive. Times of immunization are indicated by the arrows (weeks 0, 27, 41, and 60). Virus challenge was at week 63.
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tectable IFN- (95P016, 96P008, and 97P003) were pro-
tected from overt infection or cleared plasma virus rapidly.
At the time of virus challenge, all macaques had detectable
levels of serum IL-12, ranging from 161 to 933 pg/ml.
Surprisingly, we found high levels of IL-12, ranging from
350 to 650 pg/ml, in serum samples from naı¨ve animals
(data not shown), indicating that serum levels of this cyto-
kine are inherently high in pig-tailed macaques and proba-
bly were not influenced by immunization.
Discussion
The development of a vaccine for HIV-1 is now a central
focus of worldwide efforts to control AIDS. Due to the
dynamic nature of HIV infection, it is now generally ac-
cepted that any vaccine strategy will have to elicit both
humoral and cellular immune responses, which will neces-
sitate the development of new vaccine strategies to present
antigens to the immune system. Because administration of
soluble antigen alone is unlikely to stimulate both compo-
nents of the immune system, almost all of the current vac-
cine strategies for HIV include priming with a recombinant
virus vector or naked DNA, followed by boosts with appro-
priate recombinant HIV antigens. Although it is difficult to
compare primate studies directly, the results presented in
this article are comparable to others relative to the ability of
the vaccine to modulate disease progression in immunized
macaques challenged intravenously with SHIV-89.6P. In
perhaps the most successful of previous studies, in those by
Barouch et al. (2000) and Shiver et al. (2002), acute loss of
peripheral CD4 T cells generally was less than we ob-
served, but peak plasma RNA levels and clearance was
comparable to that seen in our animals immunized with
replicons and proteins.
The experiments described here clearly show that polio-
Fig. 7. Virion RNA levels of SHIV-89.6P in plasma (A, C) and absolute numbers of CD4 lymphocytes in peripheral blood (B, D) of macaques immunized
with poliovirus replicons and recombinant proteins (A, B) or only recombinant proteins (C, D) after iv challenge (week 0, vertical line in B and D) with
SHIV-89.6P. RNA copy numbers below 100 are not detectable by RT-PCR assay.
Table 2
Serum concentrations of Th1-type cytokines in macaques at time of
challengea
Animal IFN-b IL-12b Infected
96P001 908 211 Yes
96P008 15 278 Yes
97P009 15 536 Yes
95P016 15 161 /c
97P002 63 933 Yes
97P003 15 654 Yes
97P004 526 195 Yes
97P005 15 250 Yes
a Time of challenge, 63 weeks (Experiment 2).
b Concentrations are in pg/ml.
c Virus was detected only once by RT-PCR of plasma virions at 6 weeks
after challenge.
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virus replicons can be used as a vector to deliver foreign
genes to host tissues where they are expressed and elicit an
immune response. The results also demonstrate that both
antigen-specific antibodies and proliferative responses were
induced in macaques after immunization with replicons
alone. The antibody responses, however, were relatively
low, especially those induced in Experiment 2 when only
two replicons (expressing HIV-1 env and SIV gag) were
administered. Higher antibody titers were found in animals
in Experiment 1, where replicons with env genes from seven
different HIV-1 strains were used. In addition, neutralizing
antibodies to the nonpathogenic SHIV-89.6 were detected
after two immunizations with HIV-1-89.6 rgp140-Env, but
only in animals in Experiment 1. However, PBMC from
these same animals were primed to proliferate at low levels
to Gag antigen to which they were exposed only via polio-
virus replicons expressing HIV-1 gag. Likewise, in Exper-
iment 2, two intramuscular inoculations (weeks 0 and 4) of
poliovirus replicons alone were sufficient to elicit cells that
were stimulated by and incorporated [3H]thymidine upon
incubation with purified Gag protein. We were unable to test
for cytotoxic T cell activity because it is difficult to establish
and maintain autologous B cell lines for use as targets using
PBMC from pig-tailed macaques (N. Letvin and P. N. Fultz,
unpublished data). Although some animals had high levels
of IFN- in serum, there was no correlation between the
amount of circulating IFN- and rapid containment of virus
or protection against loss of CD4 T cells. This lack of
correlation with serum cytokine levels does not eliminate
the possibility of localized production of Th1-type cyto-
kines and the presence of CTL in lymph nodes or gut-
associated lymphoid tissue. Together, these data indicate
that antibodies, unless they participated in antibody-depen-
dent cellular cytotoxicity (ADCC), probably played a minor
role in the observed protection from infection or symptom-
atic disease. That all animals exhibited good proliferative
responses multiple times during the immunization period
suggests that antigen-specific T cell help was available.
Thus, it is likely that protective effects of the vaccines
resulted from some combination of CTL activity and
ADCC. It is also possible that natural killer cell activity was
important in controlling virus dissemination before adaptive
immune responses reached maximal levels.
Although the two experiments cannot be compared di-
rectly because of differences in the immunization regimens
and the number of Env proteins to which the macaques were
exposed, it is probable that the higher antibody titers and the
presence of cell-free neutralizing activity in serum samples
from the animals in Experiment 1 are related to the admin-
istration of seven replicons expressing diverse HIV-1 env
genes, compared to the animals in Experiment 2 that were
exposed only to poliovirus replicons expressing HIV-1-
LAI/IIIB env. Ljungberg et al. (2002) reported enhanced
immune responses in mice after DNA vaccination with
multiple env genes from different HIV-1 clades. Of more
relevance to our study, Cho et al. (2001) demonstrated that
recombinant vaccinia viruses expressing at least five differ-
ent HIV-1 env genes elicited broader neutralizing antibody
responses, but did not prevent infection of macaques with a
heterologous SHIV strain. Since the same rgp140-Env was
used in both of our experiments, any differences in re-
sponses probably can be attributed to the replicon immuni-
zations. That SHIV-89.6, but not SHIV-HXB2, was neu-
tralized by serum samples only after immunization with
purified protein more than likely is because, in general,
proteins administered with adjuvants are more efficient at
eliciting neutralizing antibodies than are expression vectors.
The three control macaques that received no immuniza-
tions failed to clear virions from their circulation and expe-
rienced rapid loss of greater than 95% of CD4 lympho-
cytes within 2 to 4 weeks, which is typical of SHIV-89.6P
infection in rhesus macaques (Karlsson et al., 1997). Among
the immunized animals in Experiment 2, all exhibited some
loss of CD4 lymphocytes after challenge, but most grad-
ually recovered to approximately normal levels. Two ex-
ceptions were among the animals that were immunized only
with proteins. In these two animals (97P002 and 97P005),
CD4 lymphocytes remained below 200 cells per microliter
of blood and virus loads remained greater than 105 RNA
copies per milliliter of plasma. Although having only four
animals in each group precluded an analysis of statistical
significance at 12 weeks after challenge, the mean number
of viral RNA copies per milliliter of plasma for the replicon/
protein-immunized animals was 15-fold lower than that of
the animals immunized with only protein. By 20 weeks after
challenge, this difference had increased to more than 30-
fold. That all four macaques immunized with replicons and
protein rapidly cleared virus and experienced only transient
decreases in CD4 T cells suggests that the replicons con-
tributed to enhancement of the protective effects of purified
proteins. In addition, one animal (95P016) immunized with
replicons and proteins had detectable plasma viremia only at
6 weeks after challenge and, after an initial fourfold in-
crease, had an overall decrease in virus-specific antibody
titers. This animal, therefore, appeared to control the sys-
temic infection with SHIV-89.6P successfully after immu-
nization.
Another replicon vector that has been tested as a poten-
tial vaccine for HIV was derived from VEE virus (Davis et
al., 2000). In the only macaque study reported, the overall
results were very similar to the results described here with
poliovirus replicons. Both replicons induced humoral and
cellular responses, but, in contrast to the poliovirus repli-
cons, immunization with VEE replicons alone induced low
levels of neutralizing antibodies in three of four macaques.
Although in both studies four of four immunized animals
became infected after intravenous challenge, in our study,
all four immunized animals eventually controlled plasma
viremia, whereas in the study with VEE replicons, only two
of the four macaques controlled viremia. However, because
of differences in the macaque species used, immunization
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schedules, and challenge viruses, direct evaluations of com-
parative efficacy for these two replicon vaccines is difficult.
A prime-boost strategy utilizing the poliovirus- and
VEE-based replicons has several unique and distinguishing
features. First, the vectors used to deliver antigens are RNA
rather than DNA. This aspect alone distinguishes replicons
from both naked DNA and poxvirus/adeno/adeno-associ-
ated virus delivery systems. Since replicons contain RNA,
they significantly reduce the chance of introducing foreign
genetic material into the host genome. The long-term effects
of using recombinant DNA virus vectors or the introduction
of large amounts of plasmid DNA into nonhuman primates
or humans are unknown. However, the administration of
poliovirus to humans and primates has been studied thor-
oughly for more than 50 years in association with use of the
Sabin vaccines in millions of humans in efforts to eliminate
poliomyelitis as an infectious disease (Modlin, 1995).
Second, one of the most important features of the repli-
con prime-boost strategy is the safety associated with these
vectors. Since replicons only undergo a single round of
replication, they cannot spread from cell to cell and cause
disease as other recombinant virus vaccine vectors might.
With respect to our system, the majority of the human
population has been immunized against poliovirus. It is
important to point out that poliovirus vaccines do not pro-
tect against poliovirus infection, but rather prevent multiple
rounds of replication, virus dissemination, and development
of CNS disease. Furthermore, we and other investigators
previously demonstrated that immunization against poliovi-
rus does not preclude the subsequent use of recombinant
poliovirus-based vectors that express foreign proteins (Por-
ter et al., 1997; Mandl et al., 2001). Because recombinant
poliovirus-based vectors generally are given by direct intra-
muscular inoculation instead of orally, the concentration of
neutralizing antipoliovirus antibodies in the interstitial
space of a muscle is probably too low to prevent infection of
cells in muscle tissues by recombinant poliovirus vectors.
Studies from this laboratory and from others have shown
that poliovirus can replicate in muscle tissues (Ren and
Racaniello, 1992; Porter et al., 1997). That replicon-based
vaccines do not produce infectious virus also allows safe
administration to individuals who have compromised im-
mune systems or to infants and children. Relative to this
point, the Sabin vaccine (a replication-competent, attenu-
ated virus) has an excellent safety record in infants. Since
replicons are even more attenuated, we anticipate a similar
safety profile in immunocompromised individuals and in-
fants.
Last, vaccination using poliovirus replicons can be dis-
tinguished from that using DNA vectors by the kinetics of
protein expression in vivo. We have shown that production
of proteins encoded by replicons is transient, peaking at
approximately 24 to 48 h and, in adult animals, expression
of proteins from replicons is undetectable by 96 h (Jackson
et al., 2001). While at first glance it would seem to be more
beneficial to have recombinant proteins generated for a
longer period, such as that observed for DNA-based deliv-
ery systems, administration of replicons to macaques in the
present study did successfully prime immune responses
against HIV and SIV antigens. Consistent with these results,
priming of mice with replicons encoding a variety of anti-
gens generally did not result in detectable serum antibodies
specific for the recombinant proteins (Novak et al., 1999).
However, boosting immune responses to foreign proteins
with soluble antigen resulted in the production of both IgG1
and IgG2a antibodies. In addition, we found that priming
with replicons followed by administration of soluble antigen
to mice resulted in production of IFN- by spleen cells
exposed to soluble antigen (Novak et al., 1999). Together,
these studies establish that the prime-boost strategy using
replicons and soluble antigens elicits not only antibodies but
also cell-mediated immune responses. Although the re-
sponses elicited in macaques by the replicons were gener-
ally low, the use of higher doses of replicons increased
expression of these or other viral proteins, or the inclusion
of immune modulators, such as IL-12, should amplify the
responses. Therefore, the use of poliovirus as a vector is a
valid approach that is attractive, especially because mucosal
immune responses, as observed in humans, can be induced.
Materials and methods
Animals
Juvenile and young adult pig-tailed macaques (Macaca
nemestrina) of both sexes, seronegative for antibodies to
SIV, simian T-cell lymphotropic virus type I, and simian
type-D retroviruses, were housed at the University of Ala-
bama at Birmingham (UAB) in biosafety level 2 conditions
in accordance with Animal Welfare Act guidelines. Before
all immunizations and phlebotomies, macaques were anes-
thetized with an intramuscular (im) inoculation of ketamine
(10 mg/kg). Limited physical examinations were done rou-
tinely when blood was collected for virologic and hemato-
logic evaluations. Moribund animals were euthanized with a
lethal dose of a pentobarbital solution. All procedures were
approved by the UAB Institutional Animal Care and Use
Committee.
Immunogens, immunizations, and virus challenges
For Experiment 1, the immunogens consisted of a mix-
ture of 108 infectious units (IU) each of poliovirus replicons
expressing HIV-1 p55gag and five different env genes rep-
resenting clades A, B, C, D, and E (Table 1). Some of the
env gene constructs encoded only the surface (SU) gp120
subunit, whereas others expressed both the SU and the gp41
ectodomain. In preliminary experiments, we found that all
envelope proteins were expressed from the replicons. How-
ever, the envelopes were not glycosylated and, therefore,
were not secreted from the cell. The replicons that encode
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the Gag proteins expressed p55 Gag that was released from
the cell as virus-like particles (Porter et al., 1993). Six
macaques were immunized four times (weeks 0, 4, 20, and
35) with different mixtures of replicons, which contained
108 IU of each replicon at each inoculation (Fig. 1). The first
two inoculations were administered using two routes, intra-
nasal (in) (100 l) and intrarectal (ir) (900 l), whereas the
last two inoculations were done im only. To determine
whether helper virus would enhance the immunogenicity of
the replicons, 108 IU of the Sabin poliovirus type 1 vaccine
strain (kindly provided by John Eldredge, Wyeth-Lederle)
was included in the replicon mixture that was administered
to three of the macaques (M463, M552, and M907) at weeks
0 and 4. The replicon mixture given to this same group at
weeks 20 and 35 contained an equivalent amount of Sabin
poliovirus type 2. At weeks 66 and 85, the macaques were
inoculated im with 100 g of HIV-1-89.6 rgp140-Env
(kindly provided by Robert Doms) emulsified in incomplete
Freund’s adjuvant. One of the immunized macaques died of
unknown causes at week 78; therefore, only the data for the
five remaining macaques are presented. These five animals
and three unimmunized control animals were challenged at
week 89 by iv inoculation of 1 ml of a 1:9000 dilution
(approximately 1 to 10 AID) of the pathogenic SHIV-89.6P
strain (obtained from N. Letvin, Harvard University). When
only two of the immunized macaques, and none of the
controls, became infected, as determined by multiple crite-
ria (see below), at week 116 the other three immunized
animals and the three control animals were rechallenged iv
with 10 to 100 AID of SHIV-89.6P.
In Experiment 2, four macaques were immunized im at
weeks 0, 4, and 27 with a mixture of 108 IU each of two
replicons, one expressing the HIV-1-IIIB env gene and the
other, the SIVmac239 gag gene (Fig. 1). At weeks 41 and
60, all four macaques were inoculated im with 100 g each
of purified HIV-1-89.6 rgp140-Env and SIVmac239 Gag
emulsified in incomplete Freund’s adjuvant. Four control
macaques were immunized im at weeks 53 and 60 with an
equivalent mixture of the two purified proteins. At 3 weeks
after the second protein boost, all eight macaques were
challenged with an iv inoculation of 10 to 100 AID of
SHIV-89.6P.
Serology
Antibody titers to SIV and HIV-1 were determined using
commercial ELISA kits that detect antibodies to HIV-2
(Bio-Rad) and HIV-1 (Bio-Rad/Sanofi), respectively. The
HIV-2 kit has a high degree of cross-reactivity with SIV and
is used routinely. Neutralizing antibody titers were deter-
mined against SHIV-HXB2, SHIV-89.6, and SHIV-89.6P
using a MT2 cell-killing assay, as described (Montefiori et
al., 1996). Neutralizing titers are defined as the dilution of
serum required to protect 50% of cells from the cytopathic
effects of virus, as measured by uptake of neutral red dye.
Flow cytometry
The percentages of circulating CD4 T cells were deter-
mined by flow cytometry using whole blood collected in the
presence of EDTA, phycoerythrin (PE)-labeled Leu3A
mouse anti-human monoclonal antibodies (Becton Dickin-
son), and a FACS-STAR flow cytometer. Lymphocytes
were gated by forward-scatter-versus-side-scatter size char-
acteristics.
Proliferation assays
The ability of PBMC to proliferate in response to antigen
was evaluated using a standard [3H]thymidine-incorpora-
tion assay. Briefly, 105 cells were incubated with phytohe-
magglutinin (PHA) or 2 to 3 g of purified protein or
peptide pools: HIV-1-LAI/IIIB gp120 and SF2 p24 Gag
proteins and HIV-1-89.6 Env peptides, obtained from the
NIH AIDS Research and Reference Program; HIV-1-89.6
rgp120-Env, provided by Robert Doms; or SIVmac Gag,
provided by the UAB Center for AIDS Research Molecular
Biology Core. The HIV-1-89.6 Env peptide pools consisted
of 20 peptides (20-mers) at a total concentration of 1 mg/ml
with a final concentration of each peptide in each well of 0.5
g/ml. After incubation for 5 days in a total volume of 200
l of RPMI 1640 containing 10% normal macaque or hu-
man AB serum, 1 Ci of [3H]thymidine was added to each
well of 96-well microtiter plates, which were incubated
overnight before being harvested. Control wells with PBMC
in medium alone and wells with antigen or mitogen were in
triplicate. The SI was calculated by dividing the mean cpm
incorporated by PBMC in the presence of PHA or antigen
by that in medium alone.
Virus detection and quantification
To detect the presence of PBMC containing infectious
virus, approximately 107 PBMC were cultured with an
equal number of PHA-stimulated normal human PBMC,
and cell-free culture media were monitored every 4 to 5
days for reverse transcriptase (RT) activity. Cultures
were maintained for at least 7 weeks before being dis-
carded as negative. Quantification of numbers of infec-
tious PBMC was done by limiting dilution and coculture
of PBMC, as described previously (Fultz et al., 1992).
The amount of plasma virion RNA present after virus
challenges was determined in two ways. For Experiment
1, virion RNA was quantified using the NASBA assay at
Advanced BioScience Laboratories (Kensington, MD)
(Romano et al., 1999); for Experiment 2, quantification
was done by real-time RT-PCR assay at the NCI Fred-
erick Cancer Research and Development Center (Sury-
anarayana et al., 1998).
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Measurement of cytokines
Concentrations of IFN- and IL-12 in serum samples
were measured using commercially available ELISA kits
(Biosource) optimized to recognize macaque cytokines.
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